Abiopharma

NEXTCURE, INC. (NXTC) Reports the reporting period Financial Results NEXTCURE, INC. (NXTC) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: Not disclosed
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 29743
  • Term Milestones​SIM0505 (CDH6 ADC): Phase 1 dose escalation data expected in Q2 2026SIM0505 is a novel ADC directed to cadherin
  • 6 (CDH6 ADC), overexpressed in several cancers including ovarian cancer, with limited expression in healthy tissues. SIM0505 features a proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti
  • tumor activity, fast systemic clearance and an improved potential therapeutic window. ●Received Fast Track designation for the treatment of women with PROC from the FDA.●Data from the Phase 1 open
    • targeting; our expectations regarding our ability to discover and advance product candidates using our technologies; the potential benefits of and our ability to maintain our relationship with LigaChem Biosciences, Inc., Simcere Zaiming Pharmaceutical Co, Ltd., and other third-party vendors and collaborators; our ability to retain key personnel; our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers; changes in international relations, tariffs, and other trade regulations between the U.S. and China; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing therapies; and the impact of current and future laws and regulations. ​More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.​​​​​​​​NextCure, Inc.Selected Financial Information​​​​​​​Selected Statement of Operations Items:​Three Months Ended ​​March 31, (in thousands, except share and per share amounts)​2026
    • expected in Q2 2026